Ademetionine

Ademetionine

SCHEMBL1228179

C[S+](CCC(N)C(=O)[O-])C[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@H](O)[C@@H]1O.Cc1ccc(S(=O)(=O)O)cc1.O=S(=O)(O)OS(=O)(=O)O

nearest known ligand 0.77

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Ademetionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDR known ✓ P35968 1/20 0.77
CARM1 Q86X55 2/20 0.77
PRMT5 O14744 1/20 0.77
PRMT3 O60678 1/20 0.77
ADORA3 P0DMS8 1/20 0.77
PNMT P11086 1/20 0.77
PCMT1 P22061 1/20 0.77
PRMT6 Q96LA8 1/20 0.77
PRMT1 Q99873 1/20 0.77
WDR77 Q9BQA1 1/20 0.77
NSD3 Q9BZ95 1/20 0.77
PRMT8 Q9NR22 1/20 0.77
PRMT7 Q9NVM4 1/20 0.77
AMD1 P17707 8/20 0.68
FASN P49327 1/20 0.51
NNMT P40261 2/20 0.49
MARS1 P56192 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ademetionine SCHEMBL10400453 1.00 CARM1 (0.77) CARM1PRMT5PRMT3ADORA3PNMT
Ademetionine SCHEMBL3685223 0.97 CARM1 (0.83) CARM1PRMT5PRMT3ADORA3PNMT
Ademetionine SCHEMBL1229862 0.96 CARM1 (0.81) CARM1PRMT5PRMT3ADORA3PNMT
Ademetionine SCHEMBL5465751 0.94 CARM1 (0.88) CARM1PRMT5PRMT3ADORA3PNMT
Ademetionine SCHEMBL31536258 0.90 AMD1 (0.78) CARM1PRMT5PRMT3ADORA3PNMT
Ademetionine SCHEMBL1300205 0.88 CARM1 (1.00) CARM1PRMT5PRMT3ADORA3PNMT
Ademetionine SCHEMBL25176 0.88 CARM1 (1.00) CARM1PRMT5PRMT3ADORA3PNMT
Ademetionine SCHEMBL29355793 0.88 CARM1 (1.00) CARM1PRMT5PRMT3ADORA3PNMT
Ademetionine SCHEMBL1300198 0.88 CARM1 (1.00) CARM1PRMT5PRMT3ADORA3PNMT
Ademetionine SCHEMBL4747876 0.87 CARM1 (0.98) CARM1PRMT5PRMT3ADORA3PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240316089-A1 COMBINATIONS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS KetaMed MSO, LLC 2024-09-26 US claimed
US-6759395-B2 ENTERIC COATINGS ORCHID CHEMICALS & PHARMACEUTICALS, LTD. (IN) 2004-07-06 US claimed
US-20240316089-A1 COMBINATIONS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS KetaMed MSO, LLC 2024-09-26 US disclosed
WO-2024197234-A1 COMBINATIONS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS KetaMed MSO, LLC (US) 2024-09-26 WO disclosed
US-9931356-B2 Pharmacokinetics of S-adenosylmethionine formulations METHYLATION SCIENCES INTERNATIONAL SRL (BB) 2018-04-03 US disclosed
EP-3131557-A2 NOVEL ADEMETIONINE FORMULATIONS Methylation Sciences International SRL (BB) 2017-02-22 EP disclosed
US-20170027976-A1 NOVEL ADEMETIONINE FORMULATIONS METHYLATION SCIENCES INTERNATIONAL SRL (BB) 2017-02-02 US disclosed
US-20160361339-A1 PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS BONAFIDE HEALTH, LLC 2016-12-15 US disclosed
WO-2015159155-A2 NOVEL ADEMETIONINE FORMULATIONS METHYLATION SCIENCES INTERNATIONAL SRL (BB) 2015-10-22 WO disclosed
EP-2464358-B1 IMPROVED PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS METHYLATION SCIENCES INTERNAT SRL (BB) 2015-06-17 EP disclosed
US-20140370108-A1 Pharmacokinetics of S-Adenosylmethionine Formulations METHYLATION SCIENCES INTERNATIONAL SRL (BB) 2014-12-18 US disclosed
US-20080274997-A1 Stable Granulates Containing S-adenosylmethionine and Process for Preparation Thereof CHEMISTRY AND HEALTH INTERNATIONAL BV (CH) 2008-11-06 US disclosed
WO-2007013987-A2 SUPPLEMENT COMPOSITION AND METHOD OF USE IN ENHANCEMENT OF METHYLATION PROCESS SURACELL, INC. (US) 2007-02-01 WO disclosed
US-20070021376-A1 Supplement composition and method of use in enhancement of methylation process SURACELL, INC. (US) 2007-01-25 US disclosed
US-20060275363-A1 STABLE GRANULATES CONTAINING S-ADENOSYLMETHIONINE AND PROCESS FOR PREPARATION THEREOF CHEMISTRY AND HEALTH INTERNATIONAL BV (CH) 2006-12-07 US disclosed
US-7048948-B2 Stable granulates containing S-adenosylmethionine and process for the preparation thereof CHEMISTRY & HEALTH INTERNATIONAL BV (CH) 2006-05-23 US disclosed
US-20040106573-A1 Stable granulates containing s-adenosylmethionine and process for the preparation thereof CHEMISTRY & HEALTH INTERNATIONAL BV (CH) 2004-06-03 US disclosed
EP-1325740-B1 Stable granulates containing S-Adenosylmethionine and process for the preparation thereof CHEMISTRY & HEALTH INT BV (CH) 2004-04-21 EP disclosed
EP-1325740-A1 Stable granulates containing S-Adenosylmethionine and process for the preparation thereof Chemistry & Health International B.V. (CH) 2003-07-09 EP disclosed
WO-2003053412-A1 STABLE GRANULATES CONTAINING S-ADENOSYLMETHIONNE AND PROCESS FOR THE PREPARATION THEREOF CHEMISTRY & HEALTH INTERNATIONAL B.V. (CH) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140370108-A1 Pharmacokinetics of S-Adenosylmethionine Formulations MAT1A, MAT2A, AHCY KDR 4222/4885CARM1 606/4885PRMT5 43/4885
US-20240316089-A1 COMBINATIONS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS GRIN3A, GRIN2A, GRIN2B KDR 4197/4885CARM1 909/4885PRMT5 225/4885
US-20080274997-A1 Stable Granulates Containing S-adenosylmethionine and Process for Preparation Thereof RNMT, BHMT2, MAT2A KDR 2048/4885CARM1 277/4885PRMT5 88/4885
US-20160361339-A1 PHARMACOKINETICS OF S-ADENOSYLMETHIONINE FORMULATIONS MAT1A, MAT2A, AHCY KDR 4222/4885CARM1 606/4885PRMT5 43/4885
US-20170027976-A1 NOVEL ADEMETIONINE FORMULATIONS BHMT2, MAT1A, BHMT KDR 1925/4885CARM1 228/4885PRMT5 81/4885
US-20040106573-A1 Stable granulates containing s-adenosylmethionine and process for the preparation thereof RNMT, BHMT2, GMPS KDR 1950/4885CARM1 299/4885PRMT5 79/4885
US-20060275363-A1 STABLE GRANULATES CONTAINING S-ADENOSYLMETHIONINE AND PROCESS FOR PREPARATION THEREOF RNMT, BHMT2, MAT2A KDR 2048/4885CARM1 277/4885PRMT5 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.